Our expected outcomes are:

  • A two-port AP system with automated closed –loop glycaemic control to monitor and treatment diabetes patients remotely at the point of need, independent of their location, meal intake and activities. This two-port AP system will be connected to the health care provider by a wireless telemedicine platform comprising the latest ICT connection technologies as smart phones, blue tooth etc, facilitating an improved link and interaction between patients and doctors and a more active participation of patients in their care process.
  • A risk assessment model built on heterogeneous clinical data and tested in an in silico environment and in patients in a hospital environment and at home, addressing also the needs of elderly people, a growing group of insulin treated people with diabetes;
  • A top-notch algorithm for continuous glucose monitoring for more precise assessment of the health status with an error level of less than 5%;
  • A hypo-/hyper-glycaemia alarm for safer and more accurate treatment. This alarm would improve the willingness of the patients to adopt tight glycaemic control leading to less clinical complications and hospitalisation;
  • The first prototype of a single-port AP system based on a nanoscale infusion pump architecture using biocompatible material, microneedles and miniturized drug delivery technologies based on microfluid features incorporating the e-Health application solutions of AP@home as the automated closed-loop glycaemic control, the wireless telemedicine platform, the risk assessment model, the top-notch algorithm for measuring the glucose and the hypo-/hyper-glycaemia alarm.